Cloud Hosting

Pandemic fears and frustrations are mounting. What if vaccine deals had been out in the open?

Jessica covers the good, the bad, and the ugly when it comes to big global companies and their impact in Switzerland and abroad. Shes always looking for a Swiss connection with her native San Francisco and will happily discuss why her hometown has produced some of the greatest innovations but cant seem to solve its housing crisis.

More from this author| English Department

At this time last year, all eyes were on the biopharma companies. Their vaccines were going to save us from more devastation, the endless uncertainty, and the deepening economic crisis. But here we are again, wrote the New York Times last week: Chaos rules global response to the omicron variantExternal link.

Some people are pointing the finger at rich countries for hoarding vaccines, some fault pharma companies for not sharing the formulas to manufacture them, and others blame people pushing back against vaccines and government restrictions.

Perhaps more troubling to many people is the secrecy. Its the behind-the-scenes deals with vaccine makers, explaining science as if it is a public relations exercise, and communicating clinical trial results with an eye on the share price. This virus is no doubt confusing, but it doesnt help that there is deep suspicion that pharma companies are jockeying for a position in the market or trying to win investors or reputational goodwill. HistoryExternal link explains some of this suspicion, and SWI swissinfo.ch readers offered their own thoughts in ourdebate.

With all the confusion, misunderstandings and mistrust everywhere, one cant help but wonder what would happen if there was more transparency. What if governments showed their cards and biopharma companies shared how many vaccines they sold, at what price, and their conditions? Would this have built trust? Would it have helped distribute vaccines more widely, leaving us less vulnerable to variants?

The idea is gaining some backers. Last week the Swiss House of Representatives voted in favour of making the vaccine deals with pharma companies publicExternal link. While the proposal still needs to be discussed in the Senate, the Swiss pharma industry association reacted immediately, arguing it would threaten Switzerlands reputation as a trustworthy partner. One politician voting against the majority called the idea plain stupidExternal link. Stay tuned.

What is your view? Do you think there should be more transparency? In what areas?

New responsible business law falls short of what campaigners had in mind. On Friday, the government announced the long-awaited decision on the counter proposal to the Responsible Business Initiative. The new law will come into forceExternal link in 2022 and requires large companies to report on environmental and social issues. As of 2023, some companies will also be expected to examine their supply chains for child labour and conflict minerals.

However, NGOs say there are so many exceptions and conditions in the law that it will be easy for companies to escape even these minimum requirements. For example, many raw material or commodity companies would be exempt because they have fewer than 500 companies despite huge risks from their activities. The law also doesnt require companies to assess supply chains beyond the first tier or where the finished product is assembled. Campaigners are now wondering if this is what Swiss voters had in mind when they cast their vote on the subject in November 2020.

Moreover, NGOs that were hoping changes at the EU level would compensate for any weaknesses in Swiss law are disappointed. Things seemed to be stalled indefinitely at the EU level.

Glencore plans to phase out coal mines but investors are divided about how quickly. Thats according to a story in the FT this week on the occasion of Glencores investor day. The new CEO, Gary Nagle, said that the company will close its coal minesExternal link within the next 30 years. At least one activist fund said thats too long. Bluebell Capital argues that Glencore's adherence to coal mining is "morally unacceptableExternal link and financially flawed" writes the NZZ. Some investors such as Norways sovereign wealth fund cant invest in the company because of the coal assets. Nagle and other investors though appear to defend the view that spinning off fossil fuel assets isnt the right move.

Swiss commodity traders own a lot of agriculture land around the world. According to research by NGO Public Eye, commodity traders like Olam, Raizan and COFCO, that have a major presence in Switzerland, own agriculture land equivalent to six times the arable land available in Switzerland. As commodity traders are the go-between in the supply chain, its been easier for them to evade responsibility for environmental and human rights issues in other countries. How these companies secured so much land, and the mere fact that they own so much of it, is cause for more stringent standards on the sector, argues Public Eye.

Feedback or story tips? Send me a message: jessica.davis@swissinfo.chExternal link.

Thanks for reading.

Sign up! Keep tabs on Switzerland's biggest companies, directly in your inbox

Go here to read the rest:
Suspicion of the pharma industry runs deep - SWI swissinfo.ch - swissinfo.ch